"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
| Descriptor ID |
D052216
|
| MeSH Number(s) |
D06.472.317.469.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Thompson CA, St?rmer T. Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts. Diabetes Care. 2023 02 01; 46(2):249-251.
-
Davidson MB. SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists. Ann Intern Med. 2019 12 17; 171(12):JC70.
-
Cruz B, Flores RJ, Uribe KP, Espinoza EJ, Spencer CT, Serafine KM, Nazarian A, O'Dell LE. Insulin modulates the strong reinforcing effects of nicotine and changes in insulin biomarkers in a rodent model of diabetes. Neuropsychopharmacology. 2019 05; 44(6):1141-1151.
-
Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, Patterson AD, Gonzalez FJ, Chiang JYL. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology. 2018 10; 68(4):1574-1588.
-
Xie Z, Enkhjargal B, Wu L, Zhou K, Sun C, Hu X, Gospodarev V, Tang J, You C, Zhang JH. Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats. Neuropharmacology. 2018 Jan; 128:142-151.
-
Nurunnabi M, Lee SA, Revuri V, Hwang YH, Kang SH, Lee M, Cho S, Cho KJ, Byun Y, Bae YH, Lee DY, Lee YK. Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes. J Control Release. 2017 Dec 28; 268:305-313.
-
Kilimnik G, Kim A, Steiner DF, Friedman TC, Hara M. Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic a-cells in mouse models of ?-cell regeneration. Islets. 2010 May-Jun; 2(3):149-55.
-
Little TJ, Doran S, Meyer JH, Smout AJ, O'Donovan DG, Wu KL, Jones KL, Wishart J, Rayner CK, Horowitz M, Feinle-Bisset C. The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed. Am J Physiol Endocrinol Metab. 2006 Sep; 291(3):E647-55.
-
McGirr R, Ejbick CE, Carter DE, Andrews JD, Nie Y, Friedman TC, Dhanvantari S. Glucose dependence of the regulated secretory pathway in alphaTC1-6 cells. Endocrinology. 2005 Oct; 146(10):4514-23.